PT3229810T - Análogos de éter fosfolipídico como veículos de medicamentos direcionados para o cancro - Google Patents
Análogos de éter fosfolipídico como veículos de medicamentos direcionados para o cancroInfo
- Publication number
- PT3229810T PT3229810T PT158601633T PT15860163T PT3229810T PT 3229810 T PT3229810 T PT 3229810T PT 158601633 T PT158601633 T PT 158601633T PT 15860163 T PT15860163 T PT 15860163T PT 3229810 T PT3229810 T PT 3229810T
- Authority
- PT
- Portugal
- Prior art keywords
- cancer
- targeting drug
- phospholipid ether
- ether analogs
- drug vehicles
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- -1 Phospholipid ether analogs Chemical class 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/6551—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
- C07F9/65512—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462080436P | 2014-11-17 | 2014-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3229810T true PT3229810T (pt) | 2020-08-27 |
Family
ID=55960741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT158601633T PT3229810T (pt) | 2014-11-17 | 2015-11-06 | Análogos de éter fosfolipídico como veículos de medicamentos direcionados para o cancro |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9925269B2 (pt) |
| EP (2) | EP3750545B1 (pt) |
| JP (1) | JP6832861B2 (pt) |
| KR (1) | KR102500181B1 (pt) |
| CN (2) | CN116655690A (pt) |
| AU (1) | AU2015350400B2 (pt) |
| BR (1) | BR112017010188B1 (pt) |
| CA (1) | CA2968145C (pt) |
| DK (2) | DK3750545T3 (pt) |
| EA (1) | EA037519B1 (pt) |
| ES (1) | ES2811367T3 (pt) |
| IL (1) | IL252102B (pt) |
| MX (1) | MX2017006382A (pt) |
| PT (1) | PT3229810T (pt) |
| SG (1) | SG11201703979QA (pt) |
| SI (1) | SI3229810T1 (pt) |
| TW (1) | TWI576341B (pt) |
| WO (1) | WO2016081203A2 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2811367T3 (es) * | 2014-11-17 | 2021-03-11 | Cellectar Biosciences Inc | Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer |
| US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
| MY193776A (en) * | 2015-09-22 | 2022-10-27 | Univ California | Modified cytotoxins and their therapeutics use |
| AU2016349577B2 (en) * | 2015-11-06 | 2023-10-26 | Wisconsin Alumni Research Foundation | Long-lived gadolinium based tumor targeted imaging and therapy agents |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US11633506B2 (en) | 2016-07-18 | 2023-04-25 | Wisconsin Alumni Research Foundation | Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies |
| CN109789207B (zh) | 2016-07-25 | 2022-11-18 | 威斯康星校友研究基金会 | 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物 |
| CN109789227B (zh) * | 2016-07-25 | 2022-10-11 | 威斯康星校友研究基金会 | 用于癌症成像和疗法的放射性磷脂金属螯合物 |
| AU2018219226A1 (en) * | 2017-02-07 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| CN110582288A (zh) | 2017-02-28 | 2019-12-17 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| US11779602B2 (en) | 2018-01-22 | 2023-10-10 | Endocyte, Inc. | Methods of use for CAR T cells |
| SG11202007426XA (en) * | 2018-02-06 | 2020-09-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| CA3095515A1 (en) | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| US20220125841A1 (en) * | 2019-03-13 | 2022-04-28 | Seattle Children's Hospital (dba Seattle Children'a Research Institute) | Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers |
| TWI705813B (zh) | 2019-05-24 | 2020-10-01 | 國立交通大學 | 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途 |
| EP3992276A4 (en) * | 2019-06-27 | 2022-09-07 | Showa Denko Materials Co., Ltd. | CELL SCAFFOLD MATERIAL, SUPPORT AND METHOD FOR CELL CULTURE |
| CA3150991A1 (en) | 2019-09-12 | 2021-03-18 | Cellectar Biosciences, Inc. | Phospholipid ether conjugates as cancer-targeting drug vehicles |
| BR112022006739B1 (pt) * | 2019-10-10 | 2024-01-23 | Cellectar Biosciences, Inc | Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer |
| CN114437128B (zh) * | 2022-01-28 | 2023-12-19 | 中国科学院长春应用化学研究所 | 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965391A (en) * | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| DE4408011C1 (de) | 1994-03-10 | 1995-11-02 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Tumortherapie |
| US5534499A (en) * | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| WO1998024480A1 (en) * | 1996-12-04 | 1998-06-11 | The Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
| US5837283A (en) * | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| AU3000800A (en) * | 1999-02-18 | 2000-09-04 | Supergen, Inc. | Phosphocholine linked prodrug derivatives |
| IL131887A0 (en) * | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| KR20070015518A (ko) | 2004-03-02 | 2007-02-05 | 셀렉타, 엘엘씨 | 암의 진단 및 치료를 위한 포스포리피드 유사체 |
| US7632644B2 (en) | 2004-03-02 | 2009-12-15 | Cellectar, Inc. | Imaging and selective retention of phospholipid ether analogs |
| US8540968B2 (en) | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| CN101001647A (zh) | 2004-07-08 | 2007-07-18 | 塞勒克塔有限公司 | 使用放射性标记的磷脂醚类似物的虚拟结肠镜检查 |
| CA2591907A1 (en) | 2004-12-20 | 2007-02-01 | Cellectar, Llc | Phospholipid ether analogs for detecting and treating cancer |
| CN101340918B (zh) | 2005-12-19 | 2012-10-03 | 阿特纳赞塔里斯有限公司 | 具有降低细胞毒性的新烷基磷脂衍生物及其用途 |
| US8022235B2 (en) * | 2007-06-01 | 2011-09-20 | Cellectar, Inc. | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use |
| US7893286B2 (en) | 2007-06-01 | 2011-02-22 | Cellectar, Inc. | Method for the synthesis of phospholipid ethers |
| JP5537753B2 (ja) * | 2007-11-28 | 2014-07-02 | セレーター ファーマスーティカルズ、インク． | 改良されたタキサン送達システム |
| US20100286510A1 (en) * | 2009-05-11 | 2010-11-11 | Pinchuk Anatoly | Use of fluorescent phospholipid ether compounds in biopsies |
| US20100284931A1 (en) * | 2009-05-11 | 2010-11-11 | Pinchuk Anatoly | Fluorescent phospholipid ether compounds, compositions, and methods of use |
| ES2549459T3 (es) | 2009-05-11 | 2015-10-28 | Cellectar, Inc. | Compuestos de éter de fosfolípido fluorescentes, composiciones y procedimientos de uso |
| US7811548B1 (en) | 2009-05-11 | 2010-10-12 | Cellectar, Inc. | Fluorescent phospholipid ether compounds and compositions |
| US8871181B2 (en) | 2009-05-11 | 2014-10-28 | Cellectar, Inc. | Fluorescent phospholipid ether compounds, compositions, and methods of use |
| US20100316567A1 (en) | 2009-06-12 | 2010-12-16 | Weichert Jamey P | Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells |
| JP2013504590A (ja) | 2009-09-11 | 2013-02-07 | セレクター，インコーポレイティド | 非放射性リン脂質化合物、組成物、及び使用方法 |
| US20140255432A1 (en) | 2011-07-27 | 2014-09-11 | Ohio State Innovation Foundation | Silvestrol, silvestrol analogs and uses thereof |
| ES2811367T3 (es) * | 2014-11-17 | 2021-03-11 | Cellectar Biosciences Inc | Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer |
| ES2870037T3 (es) | 2015-11-25 | 2021-10-26 | Effector Therapeutics Inc | Compuestos inhibidores de EIF4-A y métodos relacionados con los mismos |
| WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| CA3095515A1 (en) | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
-
2015
- 2015-11-06 ES ES15860163T patent/ES2811367T3/es active Active
- 2015-11-06 US US14/934,203 patent/US9925269B2/en active Active
- 2015-11-06 US US14/934,209 patent/US9345718B1/en active Active
- 2015-11-06 AU AU2015350400A patent/AU2015350400B2/en active Active
- 2015-11-06 CA CA2968145A patent/CA2968145C/en active Active
- 2015-11-06 DK DK20186803.1T patent/DK3750545T3/da active
- 2015-11-06 EA EA201791094A patent/EA037519B1/ru unknown
- 2015-11-06 MX MX2017006382A patent/MX2017006382A/es unknown
- 2015-11-06 CN CN202310088164.3A patent/CN116655690A/zh active Pending
- 2015-11-06 KR KR1020177016519A patent/KR102500181B1/ko active IP Right Grant
- 2015-11-06 EP EP20186803.1A patent/EP3750545B1/en active Active
- 2015-11-06 SG SG11201703979QA patent/SG11201703979QA/en unknown
- 2015-11-06 CN CN201580073699.7A patent/CN107708702A/zh active Pending
- 2015-11-06 BR BR112017010188-2A patent/BR112017010188B1/pt active IP Right Grant
- 2015-11-06 WO PCT/US2015/059382 patent/WO2016081203A2/en active Application Filing
- 2015-11-06 PT PT158601633T patent/PT3229810T/pt unknown
- 2015-11-06 EP EP15860163.3A patent/EP3229810B1/en active Active
- 2015-11-06 SI SI201531311T patent/SI3229810T1/sl unknown
- 2015-11-06 JP JP2017544835A patent/JP6832861B2/ja active Active
- 2015-11-06 DK DK15860163.3T patent/DK3229810T3/da active
- 2015-11-11 TW TW104137096A patent/TWI576341B/zh active
-
2016
- 2016-04-15 US US15/099,789 patent/US9480754B2/en active Active
-
2017
- 2017-05-04 IL IL252102A patent/IL252102B/en unknown
-
2018
- 2018-02-12 US US15/894,430 patent/US11439709B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252102A0 (en) | Phospholipid ether analogs as vehicles for cancer-targeting drugs | |
| IL270954A (en) | Pharmaceutical compounds | |
| SG11201610596PA (en) | Lipid comprising docosapentaenoic acid | |
| GB201404922D0 (en) | Pharmaceutical compounds | |
| HUE057834T2 (hu) | Gyógyszerészeti készítmény | |
| GB201416513D0 (en) | Pharmaceutical compounds | |
| GB201404026D0 (en) | iImprovements relating to vehicle seating | |
| SG11201610353TA (en) | Hybrid composition | |
| SG11201606267PA (en) | Short landing warning | |
| GB201417707D0 (en) | Pharmaceutical compounds | |
| GB2549885B (en) | Landing system | |
| ZA201901095B (en) | Insulin analogs | |
| IL253125A0 (en) | Preparations based on tetracaine for use as an anesthetic | |
| IL249842A0 (en) | A lipid containing docosapentanoic acid | |
| TWM490345U (en) | Drift vehicle structure | |
| GB201610206D0 (en) | Insulin cool-box for travel | |
| AU5253P (en) | MicJur05 Michelia hybrid | |
| AU5329P (en) | USCAL83901 Calibrachoa hybrid | |
| AU5328P (en) | USCAL08501 Calibrachoa hybrid | |
| GB201508022D0 (en) | Pharmaceutical compounds | |
| AU2014228V (en) | Parcleo Magnolia hybrid | |
| AU2014229V (en) | Parcind Magnolia hybrid | |
| TH1601006445A (th) | โครงสร้างสำหรับบรรจุของยานพาหนะ | |
| GB201407600D0 (en) | Extrusion for graphics | |
| GB201416968D0 (en) | Pharmaceutical compounds |